Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
Sponsor: Guangzhou JOYO Pharma Co., Ltd
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: * The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. * The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: * Be treated with either a low-dose or high-dose of JYP0061. * Undergo efficacy and safety evaluations as stipulated in the trial protocol.
Official title: An Efficacy and Safety Study of JYP0061 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2023-12-27
Completion Date
2026-10-10
Last Updated
2025-03-20
Healthy Volunteers
No
Conditions
Interventions
JYP0061 15 mg
Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.
JYP0061 30 mg
articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.
Placebo
Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.
Locations (1)
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China